SML3650

CTPI-2

≥98% (HPLC)

• 同義詞: 2-(4-Chloro-3-nitrobenzenesulfonamido)benzoic acid, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]benzoic acid, CTPI 2, CTPI2
• 經驗公式（希爾表示法）: C₁₃H₉ClN₂O₆S
• CAS號碼: 68003-38-3
• 分子量：: 356.74
• MDL號碼: MFCD00129907
• 分類程式碼代碼: 12352200
• NACRES: NA.25

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: [S](=O)(=O)(Nc2c(cccc2)C(=O)O)c1cc(c(cc1)Cl)[N+](=O)[O-]
• InChI: 1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)
• InChI 密鑰: NJTHPOSQGFJTDP-UHFFFAOYSA-N

描述

生化／生理作用

CTPI-2 is a selective mitochondrial citrate transporter (SLC25A1) inhibitor that displays H1299 anti-proliferation activity in a SLC25A1-dependent manner (IC50 <10  μM). When compared with CTPI-1, CTPI-2 exhibits 20-fold higher target affinity (hSLC25A1 KD = 3.5 μM vs. 63.6 μM, respectively) and is ~1000-fold more potent against H1299 sphere-forming capacity. CTPI-2 inhibits mitochondrial respiration and formation of patient NSCLC tumors-derived CSCs spheres in cultures (10-50 μM), as well as suppresses the growth of patent-derived NSCLC exnografts in mice in vivo (28 mg/kg q.o.d. i.p.).

Selective mitochondrial citrate transporter (SLC25A1) inhibitor with anti-cancer efficacy in cultures and in vivo.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable